Antony Blanc, PhD, serves as Chief Business Officer (CBO) of ILiAD Biotechnologies, bringing more than 25 years of expertise in building and scaling businesses across biotechnology, vaccines, and pharmaceuticals.
A molecular biologist by training — holding a PhD from McGill University — Dr. Blanc has spent his career at the intersection of science and business strategy. He began at McKinsey & Company before transitioning into operational and corporate development leadership roles at biotechnology firms in France and Switzerland. He subsequently joined GSK Vaccines, where he held senior positions spanning business development, strategic marketing, and strategic pricing, and led the integration of the Novartis Vaccines division into GSK. He later returned to McKinsey to co-lead the firm's European Biotech practice.
During the COVID-19 pandemic, Dr. Blanc served as Chief Business Officer and Chief Commercial Officer at CureVac, where he negotiated advance purchase agreements with the European Union and other governments, established key commercial and product development partnerships, and spearheaded the company's strategic pivot toward cancer vaccines.